Shanghai Shyndec Pharmaceutical Co Ltd Capital Reinvestment Ratio
Shanghai Shyndec Pharmaceutical Co Ltd capital reinvestment ratio. Shanghai Shyndec Pharmaceutical Co Ltd (600420) has a Capital Reinvestment Ratio of 0.14x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥486.04 Million) in capital expenditures (CN¥67.11 Million). Check 600420 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Shanghai Shyndec Pharmaceutical Co Ltd (2004–2025)
Capital reinvestment ratio of Shanghai Shyndec Pharmaceutical Co Ltd from 2004 to 2025. This chart tracks Shanghai Shyndec Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 22 annual periods. Also explore net asset momentum of Shanghai Shyndec Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Shanghai Shyndec Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2004–2025)
Shanghai Shyndec Pharmaceutical Co Ltd capital reinvestment ratio by year from 2004 to 2025. For the full cash flow conversion analysis, see 600420 cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | CN¥1.70 Billion | CN¥263.83 Million | ▲ +59.5% |
| 2024 | 0.10x | CN¥2.26 Billion | CN¥219.77 Million | ▼ -53.1% |
| 2023 | 0.21x | CN¥1.72 Billion | CN¥357.19 Million | ▲ +92.9% |
| 2022 | 0.11x | CN¥2.86 Billion | CN¥307.44 Million | ▼ -65.3% |
| 2021 | 0.31x | CN¥1.68 Billion | CN¥521.44 Million | ▲ +28.1% |
| 2020 | 0.24x | CN¥1.56 Billion | CN¥377.98 Million | ▼ -23.8% |
| 2019 | 0.32x | CN¥1.27 Billion | CN¥403.82 Million | ▲ +32.9% |
| 2018 | 0.24x | CN¥1.67 Billion | CN¥399.40 Million | ▲ +228.8% |
| 2017 | 0.07x | CN¥2.31 Billion | CN¥168.44 Million | ▼ -74.7% |
| 2016 | 0.29x | CN¥838.58 Million | CN¥241.30 Million | ▼ -72.2% |
| 2015 | 1.03x | CN¥226.65 Million | CN¥234.52 Million | ▼ -37.9% |
| 2014 | 1.67x | CN¥258.51 Million | CN¥430.53 Million | ▼ -32.6% |
| 2013 | 2.47x | CN¥207.50 Million | CN¥512.62 Million | ▲ +17.8% |
| 2012 | 2.10x | CN¥193.41 Million | CN¥405.52 Million | ▲ +122.3% |
| 2011 | 0.94x | CN¥136.12 Million | CN¥128.40 Million | ▼ -30.4% |
| 2010 | 1.36x | CN¥115.11 Million | CN¥156.02 Million | ▲ +322.0% |
| 2009 | 0.32x | CN¥97.43 Million | CN¥31.29 Million | ▲ +37.5% |
| 2008 | 0.23x | CN¥58.04 Million | CN¥13.56 Million | ▼ -44.2% |
| 2007 | 0.42x | CN¥82.31 Million | CN¥34.45 Million | ▼ -50.3% |
| 2006 | 0.84x | CN¥73.60 Million | CN¥62.00 Million | ▼ -31.9% |
| 2005 | 1.24x | CN¥57.90 Million | CN¥71.65 Million | ▲ +33.4% |
| 2004 | 0.93x | CN¥17.02 Million | CN¥15.79 Million | — |